Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

FWBI | First Wave BioPharma Inc

Index	-	P/E	0.03	EPS (ttm)	10.52	Insider Own	0.02%	Shs Outstand	7.15M	Perf Week	-14.65%
Market Cap	2.20M	Forward P/E	-	EPS next Y	-1.35	Insider Trans	-92.12%	Shs Float	7.15M	Perf Month	-5.20%
Income	-8.19M	PEG	-	EPS next Q	-0.61	Inst Own	0.66%	Short Float / Ratio	0.31% / 0.01	Perf Quarter	-80.50%
Sales	0.00M	P/S	-	EPS this Y	74.40%	Inst Trans	210.67%	Short Interest	0.02M	Perf Half Y	-89.73%
Book/sh	0.21	P/B	1.47	EPS next Y	55.57%	ROA	-190.29%	Target Price	14.00	Perf Year	-96.79%
Cash/sh	0.17	P/C	1.78	EPS next 5Y	-	ROE	-	52W Range	0.27 - 16.38	Perf YTD	-94.97%
Dividend	-	P/FCF	-	EPS past 5Y	60.56%	ROI	-768.01%	52W High	-98.12%	Beta	1.56
Dividend %	-	Quick Ratio	0.72	Sales past 5Y	0.00%	Gross Margin	-	52W Low	12.73%	ATR	0.09
Employees	10	Current Ratio	0.72	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	35.74	Volatility	12.00% 28.43%
Optionable	No	Debt/Eq	0.45	EPS Q/Q	96.47%	Profit Margin	-	Rel Volume	0.15	Prev Close	0.32
Shortable	Yes	LT Debt/Eq	0.20	Earnings	-	Payout	-	Avg Volume	3.62M	Price	0.31
Recom	2.00	SMA20	-19.09%	SMA50	-31.73%	SMA200	-87.95%	Volume	527,685	Change	-5.17%

Sep-15-23 08:45AM	First Wave BioPharma To Present at the BIO Investor Forum (GlobeNewswire) -13.39%
Sep-14-23 10:43AM	First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.0 Million Gross Proceeds Priced At-the-Market (GlobeNewswire) +16.75%
06:00AM	First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi (GlobeNewswire)
Sep-05-23 07:00AM	First Wave BioPharma to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) +55.17%
Jul-19-23 08:15AM	First Wave BioPharma, Inc. Announces Pricing of $2.1 Million Public Offering (GlobeNewswire)
07:00AM	Loading…
Jul-13-23 07:00AM	First Wave BioPharma Announces Initial Topline Results from Phase 2 SPAN Clinical Trial Investigating Enhanced Adrulipase Formulation (GlobeNewswire) -32.46%
Jul-05-23 07:00AM	First Wave BioPharma Chairman and CEO Issues Letter to Stockholders (GlobeNewswire)
Jun-28-23 07:00AM	First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation (GlobeNewswire)
Jun-27-23 07:00AM	First Wave BioPharma Strengthens Intellectual Property Estate (GlobeNewswire) -6.51%
Jun-15-23 11:31AM	First Wave BioPharma to Attend the 36th National Cystic Fibrosis Education Conference (July 28-30) (GlobeNewswire) +8.57%
Jun-13-23 12:50PM	First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.4 Million Gross Proceeds Priced At-the-Market (GlobeNewswire) +33.12%
07:00AM	First Wave BioPharma Reaches Enrollment Target for Phase 2 SPAN Adrulipase Clinical Trial in Cystic Fibrosis (GlobeNewswire)
May-15-23 07:00AM	First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference (GlobeNewswire)
May-11-23 07:00AM	First Wave BioPharma Completes Patient Screening For Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis (GlobeNewswire)
May-02-23 07:30AM	First Wave BioPharma to Participate in EF Hutton Inaugural Global Conference (GlobeNewswire) -7.14%
07:00AM	Loading…
Apr-25-23 07:00AM	First Wave Biopharma Exceeds 50% Enrollment Target for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis (GlobeNewswire)
Mar-13-23 08:00AM	First Wave BioPharma Announces $4.0 Million Private Placement Priced At-The-Market under Nasdaq Rules (GlobeNewswire) -16.76%
07:00AM	HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors (GlobeNewswire)
Mar-10-23 07:00AM	First Wave BioPharma Announces Second Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation in Cystic Fibrosis (GlobeNewswire)
Mar-09-23 07:00AM	First Wave BioPharma Announces First Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation (GlobeNewswire) +6.48%
Feb-28-23 07:00AM	First Wave BioPharma to Participate in Fireside Chat at the 35th Annual Roth Conference (GlobeNewswire)
Feb-21-23 07:00AM	First Wave BioPharma Announces Phase 2 Adrulipase Combination Trial Data to be Presented at the 2023 Digestive Disease Week (DDW) Conference (GlobeNewswire) +7.14%
Feb-13-23 07:00AM	First Wave BioPharma Chairman and CEO Issues Letter to Stockholders (GlobeNewswire) -6.30%
Feb-07-23 07:00AM	First Wave BioPharma Regains Compliance With Nasdaqs Minimum Bid Price Requirement (GlobeNewswire)
Feb-02-23 07:00AM	First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis (GlobeNewswire) +5.03%
Jan-31-23 07:00AM	First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis (GlobeNewswire) -7.51%
Jan-30-23 07:00AM	First Wave BioPharma to Present at the BIO CEO & Investor Conference (GlobeNewswire) +7.92%
Jan-25-23 07:00AM	First Wave BioPharma Announces Expansion of Adrulipase Intellectual Property Portfolio (GlobeNewswire) +22.17%
Jan-24-23 07:00AM	First Wave BioPharma to Present at Sequire Biotechnology Conference (GlobeNewswire)
Jan-13-23 04:00PM	First Wave BioPharma Provides Update on IND Filing For Phase 2 Trial of Enhanced Microgranule Formulation of Adrulipase for Exocrine Pancreatic Insufficiency (GlobeNewswire) -11.99%
10:20AM	Loading…
10:20AM	First Wave BioPharma Announces Results of Special Meeting of Stockholders (GlobeNewswire)
Jan-09-23 09:10AM	First Wave BioPharma Announces Adjournment of Special Meeting (GlobeNewswire) -13.33%
Jan-05-23 09:45AM	ZyVersa Therapeutics Appoints Three New Board Members (PR Newswire)
Dec-12-22 07:30AM	First Wave BioPharma to Participate in BIO Partnering @ JPM During J.P. Morgan Week 2023 (GlobeNewswire)
Dec-05-22 07:00AM	First Wave BioPharma Announces Initial Clinical Sites for its Phase 2 Trial of Enhanced Microgranule Delivery Formulation of Adrulipase (GlobeNewswire)
Nov-30-22 07:00AM	First Wave BioPharma Files Investigational New Drug Application for Enhanced Microgranule Delivery Formulation of Adrulipase (GlobeNewswire) +5.60%
Nov-25-22 05:45PM	First Wave BioPharma Announces Distribution of Series F Preferred Stock to Holders of Its Common Stock (GlobeNewswire)
Nov-22-22 04:15PM	First Wave BioPharma, Inc. Announces Closing of Private Placement (GlobeNewswire)
Nov-21-22 08:00AM	First Wave BioPharma, Inc. Announces Private Placement (GlobeNewswire) -11.61%
Nov-16-22 07:00AM	First Wave BioPharma Chairman and CEO Issues Letter to Stockholders (GlobeNewswire)
Oct-31-22 07:00AM	First Wave BioPharma Engages Rho to Manage Phase 2 Clinical Trial of Enhanced Adrulipase Formulation (GlobeNewswire)
Oct-11-22 05:30PM	First Wave BioPharma, Inc. Announces Closing of $6.0 Million Public Offering (GlobeNewswire)
Oct-10-22 07:00AM	First Wave BioPharma Presents Research Demonstrating Benefits of Improved Adrulipase Drug Delivery Formulation at AAPS 2022 PharmSci 360 (GlobeNewswire)
Oct-06-22 09:00PM	First Wave BioPharma, Inc. Announces Pricing of $6.0 Million Public Offering (GlobeNewswire) -11.96%
08:05AM	In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews James Sapirstein CEO, First Wave BioPharma, Inc. (ACCESSWIRE)
Sep-28-22 07:00AM	First Wave BioPharmas CEO James Sapirstein to Present at Inaugural Roth Healthcare Opportunities Conference (GlobeNewswire)
Sep-19-22 07:00AM	First Wave BioPharma Chairman and CEO Issues Letter to Stockholders (GlobeNewswire) -9.25%
Sep-14-22 07:00AM	First Wave BioPharma CEO James Sapirstein to Moderate Panel Discussion at Longwood Healthcare Leaders Fall Webconference (GlobeNewswire) -12.15%
Sep-07-22 07:00AM	First Wave BioPharma Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation (GlobeNewswire) -23.22%
Aug-31-22 07:00AM	First Wave BioPharma Announces AAPS 2022 PharmSci 360 Accepts Adrulipase Formulation Abstract (GlobeNewswire) -5.54%
Aug-29-22 07:00AM	First Wave BioPharma to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022 (GlobeNewswire)
Aug-25-22 12:00PM	First Wave BioPharma, Inc. Announces Reverse Stock Split (GlobeNewswire) -18.18%
Jul-15-22 08:00AM	First Wave BioPharma, Inc. Announces Private Placement (GlobeNewswire) -21.38%
May-17-22 07:00AM	First Wave BioPharma to Participate in Fireside Chat at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +6.94%
Apr-29-22 04:30PM	First Wave BioPharma Chairman and CEO Issues Letter to Shareholders (GlobeNewswire)
Apr-27-22 07:00AM	First Wave BioPharma Forms Clinical Steering Committee Focused on Advancing Inflammatory Bowel Disease (IBD) Product Portfolio (GlobeNewswire)
Mar-31-22 08:15AM	Goldman Small Cap Research Publishes New Research Report on First Wave BioPharma, Inc. (ACCESSWIRE)
Mar-28-22 04:23PM	First Wave BioPharma Files U.S. and PCT Patent Applications for Niclosamide in Long-Haul COVID-19 (GlobeNewswire)
Mar-22-22 07:00AM	First Wave BioPharma to Participate in Maxims 2022 Virtual Growth Conference (GlobeNewswire)
Mar-08-22 07:00AM	First Wave BioPharma to Participate in Fireside Chat at the 34th Annual Roth Conference (GlobeNewswire)
Mar-03-22 07:00AM	First Wave BioPharma Announces Poster Presentation at the 2022 Digestive Disease Week (DDW) Conference (GlobeNewswire)
Mar-02-22 05:00PM	First Wave BioPharma, Inc. Announces Closing of $9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Mar-01-22 07:00AM	First Wave BioPharma Announces Appointment of Sarah Romano as Chief Financial Officer (GlobeNewswire)
Feb-28-22 08:01AM	First Wave BioPharma, Inc. Announces $9 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules (GlobeNewswire) -5.95%
Feb-07-22 07:30AM	First Wave BioPharma to Participate in the 2022 BIO CEO & Investor Conference (GlobeNewswire) +6.62%
Jan-17-22 10:30AM	New to The Street TV Announces Episodes Airing on the Fox Business Network, Tonight, Monday, January 17, 2022, at 10:30 PM PT and Tomorrow Night, Tuesday, January 18, 2022, at 10:30 PM PT (GlobeNewswire)
Jan-14-22 11:25AM	UPDATE - New to The Street TV / Newsmax TV announces its Eight Interviews for This Weeks TV Broadcast, Episode #291, January 16, 2022, 10-11 AM ET (GlobeNewswire)
09:00AM	New to The Street TV / Newsmax TV announces its Eight Interviews for This Weeks TV Broadcast, Episode #290, January 16, 2022, 10-11 AM ET (GlobeNewswire)
Jan-13-22 07:00AM	First Wave BioPharma Provides Update on Adrulipase (FW-EPI) Clinical Program (GlobeNewswire)
Jan-07-22 09:16AM	First Wave BioPharma Announces Further Adjournment of Annual Meeting (GlobeNewswire)
Jan-06-22 07:00AM	First Wave BioPharma Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections (GlobeNewswire)
Jan-04-22 07:00AM	First Wave BioPharma to Participate in Two Investor Conferences in January 2022 (GlobeNewswire)
Dec-27-21 02:00PM	New to The Street TV Announces its 283rd and 284th Shows with Four Corporate Interviews, Airing on Fox Business Network, Tonight, Monday, December 27, 2021, at 10:30 PM PST and Tomorrow Night, Tuesday, December 28, 2021, at 10:30 PM PST (GlobeNewswire) -5.44%
Dec-23-21 11:45AM	New to The Street / Newsmax TV Announces Its 281st Broadcast, 8 Interviews, Airing Sunday, December 26, 2021, 1011 A.M. ET (GlobeNewswire)
Dec-17-21 09:06AM	First Wave BioPharma Announces Adjournment of Annual Meeting (GlobeNewswire)
Dec-13-21 07:00AM	First Wave BioPharma Chairman and CEO Issues Letter to Shareholders (GlobeNewswire) -6.29%
Dec-09-21 07:00AM	First Wave BioPharma Names Brian Feagan, M.D., to Scientific Advisory Board (GlobeNewswire)
Dec-06-21 07:00AM	First Wave BioPharmas CEO and President, James Sapirstein, to Participate in CEO Panel Discussion at 2021 BioFlorida Conference (GlobeNewswire)
Nov-30-21 07:00AM	First Wave BioPharma Announces Independent Data Monitoring Committee Provides Positive Interim Safety Assessment for Part 2 COVID-19 RESERVOIR Clinical Trial of Niclosamide for the Treatment of Gastrointestinal Infections (GlobeNewswire) +8.47%
Nov-16-21 07:00AM	First Wave BioPharma Announces Restructuring of Merger Consideration Payment Terms With Former Shareholders of First Wave Bio (GlobeNewswire) -7.36%
Oct-21-21 07:30AM	First Wave BioPharma Forms Steering Committee for Phase 2a PASSPORT Clinical Trial to Evaluate FW-ICI-AC in Cancer Patients with Immune Checkpoint Inhibitor-Associated Colitis (GlobeNewswire)
Oct-19-21 09:24AM	First Wave BioPharma Announces FDA Clearance of IND Application for Phase 2a PASSPORT Trial of FW-ICI-AC as Treatment for Immune Checkpoint Inhibitor-Associated Colitis (GlobeNewswire)
Oct-14-21 09:00AM	First Wave BioPharma Announces Dosing of First Patient in Phase 2b Clinical Trial Evaluating Topical Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis (GlobeNewswire)
Oct-12-21 08:30AM	First Wave BioPharma Announces Two Additions to Scientific Advisory Board (GlobeNewswire)
Oct-04-21 11:45AM	FMW Media, Inc.s New to The Street TV Announces its 5 TV Interviews Being Broadcasted on Fox Business Network, Tonight, Monday, October 4, 2021, at 10:30 P.M. PT and Tomorrow Night, Tuesday, October 5, 2021, at 10:30 P.M. PT (GlobeNewswire)
Oct-01-21 12:30PM	New to The Street / Newsmax TV Announces 8 Interviews for this Weeks TV Broadcast, October 3, 2021, airing at 10-11 AM ET (GlobeNewswire)
Sep-28-21 08:00AM	First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis (GlobeNewswire) -6.47%

First Wave Biopharma, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The firm is involved in a therapeutic development pipeline populated with multiple clinical stage programs built around its proprietary technologies, such as Niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its programs include FW-UP, FW-UC, FW-CD, FW-COV, FW-ICI-AC, MS1819, COVID-19 GI infections, and FW-EPI. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CASAMENTO CHARLES J	Director	Sep 15	Sale	0.43	10	4	6,098	Sep 18 05:44 PM
CASAMENTO CHARLES J	Director	Aug 31	Sale	0.30	6,053	1,816	6,108	Sep 05 08:08 PM
SAPIRSTEIN JAMES	President and CEO	Jul 03	Sale	1.54	3,349	5,157	36,161	Jul 05 04:27 PM
Romano Sarah	Chief Financial Officer	Jul 03	Sale	1.54	1,977	3,045	17,476	Jul 05 04:28 PM
SAPIRSTEIN JAMES	President and CEO	Apr 03	Sale	2.50	3,347	8,368	39,510	Apr 05 04:07 PM
Romano Sarah	Chief Financial Officer	Apr 03	Sale	2.50	1,975	4,938	19,453	Apr 05 04:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FWBI | First Wave BioPharma Inc

Upgrade your FINVIZ experience